Roivant Sciences Ltd. (ROIV) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, ROIV scores 44 out of 100, a D grade labeled "Roarable Sell — Underperform / Distribution Warning." The Fundamental Cash Engine pillar scores 8 out of 20, reflecting ROIC of -14% and FCF yield of -2.8%; for a prospective investor, this means the business is not currently generating returns on invested capital or free cash flow to shareholders. The Whale 13F Flow pillar scores 16 out of 20, indicating institutional accumulation and options positioning that is the strongest component of the rating and a potential upside driver if sustained. The Insider Conviction pillar scores 3 out of 20 based on SEC Form 4 and Congressional PTR cluster flow, the weakest pillar and a notable caution signal. The Macro Regime Fit pillar scores 9 out of 20, reflecting Beta of 1 and sector sensitivity. The Forensic Balance Sheet pillar scores 8 out of 20, citing Altman Z-Score of 26, Piotroski F-Score of 3 out of 9, and Debt/Equity of 0.02; the very high Altman Z-Score and very low leverage contrast with the weak Piotroski reading, which points to balance-sheet strength alongside weak operating quality. Taken together, the rating frames a valuation tradeoff: forward P/E of 28 is cited in the source data while trailing earnings are negative, so any investment case rests on expectations for future earnings rather than current cash generation. This is analytical context, not personalized financial advice.

Roivant Sciences Ltd. (ROIV) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the profile. The source data does not describe its products, customers, or revenue model beyond the reported financial figures. Reported revenue declined from $32.7M (FY 2023) to $29.1M (FY 2024) to $8.3M (FY 2025), per the SEC financials. Market capitalization is $27.1B, per the market data.

Per the SEC financials, operating margin and net margin are each -60% and gross margin is 0%, per the market data. ROIC is -14%, per the market data and RQD pillar. The Altman Z-Score is 26 and the Piotroski F-Score is 3 out of 9, per the Roarable RQD rating. Debt/Equity is 0.02, and the most recent reported cash balance is $1478.3M against debt of $113.0M, per the SEC financials and RQD pillar.

Per the recent news wire, the most significant catalyst item is a Seeking Alpha report headlined as a stock gain on a late-stage trial win, flagged GREEN as a CATALYST. Other items from Yahoo Finance Australia, Simply Wall St, Yahoo Finance, Benzinga, and Moomoo are flagged YELLOW as MARKET WIRE and largely describe market action, institutional positioning, and valuation commentary; one Yahoo Finance item frames the stock as fully priced after a 393% run. Risk watch: the 52-week range of $19.3 to $42.5 and the reported negative operating income and FCF. Proprietary signals: none are listed in the Butterfly Supply-Chain Graph.

• What specific late-stage trial was referenced in the catalyst news, and what is its status?
• What are ROIV's products, customers, and revenue sources, given revenue declined to $8.3M in FY 2025?
• What drove the reported FY 2023 net income of $4348.9M against operating cash burn in every period shown?
• What is the trailing P/E and EV/EBITDA, which are not available in the source data?
• Which institutions and insiders hold shares, given the holders section is empty?